Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib Combinations in Newly Diagnosed Multiple Myeloma
NCT01881789Phase 2Terminated
- Sponsor
- Amgen
- Start
- Oct 2013
- Primary completion
- Sep 2019
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of oprozomib in multiple myeloma (MM), sponsored by Amgen. Started Oct 2013; status: terminated.
02
Drugs
oprozomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01881789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01881789.